Table 2 Observed outcomes for HR-HPV positive women in the three genotyping laboratories combined

	N	Yes	Unknown	Proportion Yes
Baseline
HR-HPV+	127,238	16,097	258	12.7%
Cytology + if HR-HPV +	16,097	5287	0	32.8%
Had colposcopy if HR-HPV+/cytology+ after a record of referral	5287	5163	0	97.7%
PPV of colposcopy for CIN2+ if HR-HPV+/cytology+	5163	2135	0	41.4%
PPV of colposcopy for CIN3+ if HR-HPV+/cytology +	5163	1367	0	26.5%
Early recall at 12 months (HR-HPV+/cytology- at baseline)
Had early recall testing after a record of referral	10,810	8964	125	83.9%
HR-HPV +	8964	5263	0	58.7%
Cytology + if HR-HPV +	5263	1410	23	26.8%
Had colposcopy if HR-HPV+/cytology+ after a record of referral	1410	1353	0	96.0%
PPV of colposcopy for CIN2+ if HR-HPV+/cytology+	1353	473	0	35.0%
PPV of colposcopy for CIN3+ if HR-HPV+/cytology+	1353	269	0	19.9%
Cytology- if HR-HPV+	5263	3830	23	72.8%
HPV 16 or 18+ if HR-HPV+/cytology−	3830	1072	0	28.0%
Had colposcopy if HPV 16 or 18+/cytology- after a record of referral	1072	789	233	94.0%
PPV of colposcopy for CIN2+ if HPV 16 or 18+ /cytology−	789	103	0	13.1%
PPV of colposcopy for CIN3+ if HPV 16 or 18+/cytology−	789	55	0	7.0%
Early recall at 24 months (HR-HPV other+/cytology− at baseline and HR-HPV+/cytology− at 12-month early recall)
Had early recall testing after a record of referral	2758	2091	48	77.2%
HR-HPV+	2091	1368	0	65.4%
Had colposcopy after a record of referral	1368	1144	23	85.1%
PPV of colposcopy for CIN2+ if HR-HPV+	1144	117	0	10.2%
PPV of colposcopy for CIN3+if HR-HPV+	1144	56	0	4.9%
Early recall at 24 months (HPV 16 or 18+/cytology− at baseline and HR-HPV+/cytology− at 12-month early recall)^a
HR-HPV+	98	73	0	74.5%

Gray cells: Proportions of women who adhered to the type of clinical follow-up recommended by the protocol, calculated after exclusion of category “unknown” from the denominator (if non-zero). Where the “unknown” category was larger than zero, the value refers to women who had no record of referral to the type of follow-up that would be expected following the recommendations; for them, we assumed that their outcomes would be the same as the outcomes among women who had the correct record of referral. All other proportions are calculated using values in column “N” as the denominator, as there the “unknown” cells represent e.g. invalid testing outcomes (a normal occurrence in routine screening, which leads to tailored follow-up recommendations).
CIN cervical intraepithelial neoplasia, HR-HPV high-risk human papillomavirus, any of the 14 high-risk genotypes detectable by the Cobas and RealTime assays unless otherwise specified, PPV positive predictive value.
^aData from the fourth pilot laboratory, which recorded HR-HPV genotyping information using a DNA assay but did not use it for clinical management of HR-HPV positive women

Search